Cargando…

Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes

BACKGROUND: Screening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group for PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into tho...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldfield, Lucy, Evans, Anthony, Rao, Rohith Gopala, Jenkinson, Claire, Purewal, Tejpal, Psarelli, Eftychia E., Menon, Usha, Timms, John F., Pereira, Stephen P., Ghaneh, Paula, Greenhalf, William, Halloran, Christopher, Costello, Eithne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741427/
https://www.ncbi.nlm.nih.gov/pubmed/34990893
http://dx.doi.org/10.1016/j.ebiom.2021.103802
_version_ 1784629487853371392
author Oldfield, Lucy
Evans, Anthony
Rao, Rohith Gopala
Jenkinson, Claire
Purewal, Tejpal
Psarelli, Eftychia E.
Menon, Usha
Timms, John F.
Pereira, Stephen P.
Ghaneh, Paula
Greenhalf, William
Halloran, Christopher
Costello, Eithne
author_facet Oldfield, Lucy
Evans, Anthony
Rao, Rohith Gopala
Jenkinson, Claire
Purewal, Tejpal
Psarelli, Eftychia E.
Menon, Usha
Timms, John F.
Pereira, Stephen P.
Ghaneh, Paula
Greenhalf, William
Halloran, Christopher
Costello, Eithne
author_sort Oldfield, Lucy
collection PubMed
description BACKGROUND: Screening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group for PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into those with type 2 diabetes mellitus (T2DM) and those with the less prevalent PDAC-related diabetes (PDAC-DM), a form of type 3c DM commonly misdiagnosed as T2DM. METHODS: Using mass spectrometry- and immunoassay-based methodologies in a multi-stage analysis of independent sample sets (n=443 samples), blood levels of 264 proteins were considered using Ingenuity Pathway Analysis, literature review and targeted training and validation. FINDINGS: Of 30 candidate biomarkers evaluated in up to four independent patient sets, 12 showed statistically significant differences in levels between PDAC-DM and T2DM. The combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) showed strong diagnostic potential, (AUC of 0.91; 95% CI: 0.84-0.99) for the distinction of T3cDM from T2DM. INTERPRETATION: Adiponectin and IL-1Ra warrant further consideration for use in screening for PDAC in individuals newly-diagnosed with T2DM. FUNDING: North West Cancer Research, UK, Cancer Research UK, Pancreatic Cancer Action, UK.
format Online
Article
Text
id pubmed-8741427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87414272022-01-12 Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes Oldfield, Lucy Evans, Anthony Rao, Rohith Gopala Jenkinson, Claire Purewal, Tejpal Psarelli, Eftychia E. Menon, Usha Timms, John F. Pereira, Stephen P. Ghaneh, Paula Greenhalf, William Halloran, Christopher Costello, Eithne EBioMedicine Article BACKGROUND: Screening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group for PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into those with type 2 diabetes mellitus (T2DM) and those with the less prevalent PDAC-related diabetes (PDAC-DM), a form of type 3c DM commonly misdiagnosed as T2DM. METHODS: Using mass spectrometry- and immunoassay-based methodologies in a multi-stage analysis of independent sample sets (n=443 samples), blood levels of 264 proteins were considered using Ingenuity Pathway Analysis, literature review and targeted training and validation. FINDINGS: Of 30 candidate biomarkers evaluated in up to four independent patient sets, 12 showed statistically significant differences in levels between PDAC-DM and T2DM. The combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) showed strong diagnostic potential, (AUC of 0.91; 95% CI: 0.84-0.99) for the distinction of T3cDM from T2DM. INTERPRETATION: Adiponectin and IL-1Ra warrant further consideration for use in screening for PDAC in individuals newly-diagnosed with T2DM. FUNDING: North West Cancer Research, UK, Cancer Research UK, Pancreatic Cancer Action, UK. Elsevier 2022-01-03 /pmc/articles/PMC8741427/ /pubmed/34990893 http://dx.doi.org/10.1016/j.ebiom.2021.103802 Text en Crown Copyright © 2021 Published by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oldfield, Lucy
Evans, Anthony
Rao, Rohith Gopala
Jenkinson, Claire
Purewal, Tejpal
Psarelli, Eftychia E.
Menon, Usha
Timms, John F.
Pereira, Stephen P.
Ghaneh, Paula
Greenhalf, William
Halloran, Christopher
Costello, Eithne
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title_full Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title_fullStr Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title_full_unstemmed Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title_short Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
title_sort blood levels of adiponectin and il-1ra distinguish type 3c from type 2 diabetes: implications for earlier pancreatic cancer detection in new-onset diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741427/
https://www.ncbi.nlm.nih.gov/pubmed/34990893
http://dx.doi.org/10.1016/j.ebiom.2021.103802
work_keys_str_mv AT oldfieldlucy bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT evansanthony bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT raorohithgopala bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT jenkinsonclaire bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT purewaltejpal bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT psarellieftychiae bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT menonusha bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT timmsjohnf bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT pereirastephenp bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT ghanehpaula bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT greenhalfwilliam bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT halloranchristopher bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes
AT costelloeithne bloodlevelsofadiponectinandil1radistinguishtype3cfromtype2diabetesimplicationsforearlierpancreaticcancerdetectioninnewonsetdiabetes